Cambridge, MA-based Amylyx Pharmaceuticals Inc. announced that it has secured a $5M Series A financing round to support its Phase II trial of AMX0035 in ALS. The trial will test efficacy of this combination drug of sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA), both of which have individually been tested in ALS clinical trials, and have shown efficacy in cellular and animals models (see Jun 2016 news). One of the investors to join this round was the ALS Investment Fund, an ALS-specific venture fund founded by three Dutch entrepreneurs and ALS patients (see April 2014 news). Submission of the investigational new drug (IND) application is planned for later this year, followed by opening of the clinical trial for enrollment shortly thereafter.
disease-als topic-clinical topic-randdShare this: